28 October 2019 - Australia’s medicine subsidy agency has been slammed by migraine sufferers after it failed to cover the cost of a revolutionary drug that can lower the frequency and severity of the conditions.

Migraine sufferers have slammed Australia’s medicine subsidy agency for failing to cover the cost of a revolutionary drug they say can give them their life back.

Pharmaceutical giant Novartis has withdrawn latest its bid to gain a subsidy for its migraine prevention drug Aimovig after its first two applications were refused by the Pharmaceutical Benefits Advisory Committee.

Read Herald Sun article